Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab in First-Line PD-L1 High NSCLC
2024-519671-26-00Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Valemetostat Tosylate + Pembrolizumab with Pembrolizumab Monotherapy (2 arms). Primary endpoints: Number of Participants with Dose-Limiting Toxicities (DLTs), Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Other Safety Parameters and 1 more. Started Sep 2025; status: completed.
02
Drugs
valemetostatpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-519671-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519671-26-00.